GDF-15 in solid vs non-solid treatment-naïve malignancies.
Henrike ArfstenAnna ChoClaudia FreitagMarkus RadererGeorg GoliaschPhilipp E BartkoRaphael WurmGuido StrunkHeinz GisslingerChristine MarosiGabriela KornekChristoph ZielinskiMartin HülsmannNoemi PavoPublished in: European journal of clinical investigation (2019)
Elevated plasma GDF-15 is associated with progressing disease severity and poor prognosis in solid tumours of treatment-naïve cancer patients. GDF-15 increase is accompanied by worsening systemic inflammation and a subclinical functional impairment of different organs including the heart. GDF-15 represents a promising target for our pathophysiologic understanding in cardio-oncology linking conditions of both cardiac and neoplastic disease.